同和药业：公司阿戈美拉汀、奥吡卡朋原料药获得韩国市场准入资格

Core Viewpoint - The company has received market access approval for its active pharmaceutical ingredients, Agomelatine and Oxycodone, in South Korea, which will positively impact its international market expansion efforts [1] Group 1 - The company announced the receipt of drug registration certificates from the South Korean Ministry of Food and Drug Safety [1] - The approval signifies that Agomelatine and Oxycodone have gained entry into the South Korean market [1] - This development is expected to enhance the company's ability to expand its international business operations [1]